TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
TG THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$53.30−0.67 (-1.24%)
Close on Oct 19, 2026
- Market cap
- $8.38B
- P/E (TTM)
- 19.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
83.7%
Operating margin
20.0%+180016.1 pts over 5 years
Net margin
72.6%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +87.3% | +504.9% | +426.7% | – | |
| Gross profit | +77.5% | +489.2% | – | – | |
| Operating income | +194.1% | – | – | – | |
| Net income | +1812.4% | – | – | – | |
| EPS, diluted | +1746.7% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 102.8% | |
| Return on assets | – | – | 54.5% | |
| Current ratio | 3.01 | 6.99 | 4.10 | |
| Debt to equity | – | 0.06 | 0.38 | |
| Net debt to EBITDA | – | – | 1.35× | |
| Interest coverage | – | -43.2× | 4.6× | |
| Inventory turnover | – | – | 0.9× | |
| Capex to revenue | 226.3% | 234.9% | 0.0% | |
| Diluted shares | 49M | 115M | 161M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Tg Therapeutics generated $568.51M from operations and spent $100.67M on capital expenditure, dividends and share buybacks. 1% of that went back into the business.
Generated
$568.51M
Used
$100.67M
Capital expenditure$674.00K1%Dividends$00%Share buybacks$100.00M99%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin72.6%
×Asset turnover0.75×
×Equity multiplier1.89×
=Return on equity, FY2025102.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 72.6% | 0.75× | 1.89× | 102.8% |
| FY2024 | 7.1% | 0.73× | 2.37× | 12.2% |
| FY2023 | 5.4% | 0.89× | 2.39× | 11.6% |
| FY2022 | -8036.3% | 0.01× | 1.94× | -151.4% |
| FY2021 | -5204.1% | 0.01× | 1.33× | -92.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$447.18M
- Cash generatingOperating cash flow above zero-$24.77M
- Return on assets improvedROA up on the prior year7.1% → 77.4%
- Earnings backed by cashOperating cash flow above net income-$24.77M vs $447.18M
- Less leverageLong-term debt to assets fell42.3% → 23.1%
- Better liquidityCurrent ratio rose6.25 → 4.10
- No dilutionShare count did not rise160M → 161M
- Gross margin improvedGross margin up on the prior year88.30% → 83.66%
- More efficientAsset turnover rose1.00 → 1.07